Intellia Therapeutics, Inc - NTLA STOCK NEWS

Intellia Therapeutics (NASDAQ:NTLA) announced that interim Phase 1 data from its lead CRISPR therapy, NTLA-2001, will be presented on June 26. This therapy aims to treat transthyretin amyloidosis (ATTR) with a single, systemically administered dose. The ongoing trial targets hereditary ATTR amyloidosis with polyneuropathy. Initial results will assess safety and pharmacodynamics, presenting a potential breakthrough in treatment compared to the traditional lifelong therapies. Following the Phase 1 trial, further studies will evaluate NTLA-2001's effectiveness in a broader ATTR population.

Intellia Therapeutics (NASDAQ:NTLA) reported first-quarter 2021 results, ending March 31 with $600.8 million in cash. The company plans to announce initial safety data for NTLA-2001, a CRISPR-based therapy for transthyretin amyloidosis (ATTR), in mid-2021 and to submit IND applications for NTLA-5001 (acute myeloid leukemia) and NTLA-2002 (hereditary angioedema) in 2021. Research and development expenses increased to $39.3 million due to advancements in key programs. The company recorded a net loss of $46.2 million, up from $31.8 million year-over-year.

Intellia Therapeutics (NASDAQ:NTLA) announced it will present its first quarter 2021 financial results and operational highlights on May 6, 2021, at 8 a.m. ET. The conference call will allow investors to understand the company's progress in developing proprietary therapeutics using CRISPR/Cas9 technology. U.S. callers can dial 1-833-316-0545; international callers should use 1-412-317-5726. A replay will be available on the company's website later that day.

Intellia Therapeutics (NASDAQ:NTLA) announced updated preclinical data on CRISPR/Cas9-mediated gene insertion for treating alpha-1 antitrypsin deficiency (AATD) at the ASGCT Annual Meeting, held virtually from May 11-14, 2021. The findings suggest a potential to restore normal AAT protein levels after a single dose, showcasing Intellia's commitment to innovative treatments. Presentations from key executives will cover topics such as genome editing strategies and on-target safety assessments. Further information is expected to be released during the meeting.

Intellia Therapeutics (NASDAQ: NTLA) has appointed Dr. Georgia Keresty to its Board of Directors, enhancing its leadership team. Dr. Keresty brings over 35 years of pharmaceutical experience, having held senior roles in leading companies like Takeda, Johnson & Johnson, and Bristol-Myers Squibb. Her expertise encompasses transitioning therapeutic programs to clinical development and improving manufacturing processes. Intellia aims to leverage her knowledge as it advances its CRISPR/Cas9 technology towards curative therapies.

Intellia Therapeutics (NASDAQ:NTLA) has received orphan drug designation from the European Commission for NTLA-2001, aimed at treating transthyretin amyloidosis (ATTR). This investigational CRISPR therapy is the first of its kind to be delivered systemically via intravenous dosing, targeting the TTR gene responsible for producing misfolded proteins. This milestone is significant for the ATTR community, where no existing cure is available. The therapy shows potential to halt and reverse ATTR progression and is part of a co-development agreement with Regeneron.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is set to present its first preclinical data on a new cytosine deaminase base editor technology at the Cold Spring Harbor Laboratory virtual meeting, running from March 24-26, 2021. The data highlights the ability of the company’s proprietary base editors to enable multiple gene knockouts without increasing translocation rates. CEO John Leonard emphasizes the expansion of their genome editing platform for developing therapies for severe diseases. The presentation details include an impressive T cell editing efficiency of over 90% while maintaining standard translocation levels.

Intellia Therapeutics (NASDAQ: NTLA) showcased promising preclinical data on March 10, 2021, regarding non-viral genome editing of hematopoietic stem cells (HSCs) in mouse models. This innovative approach aims to address inherited blood disorders such as sickle cell disease (SCD). Key findings included durable, dose-dependent gene editing in bone marrow and HSCs, with effects lasting over a year. Intellia's proprietary lipid nanoparticles facilitated the safe delivery of CRISPR/Cas9, potentially revolutionizing treatment options for patients globally without the need for invasive procedures.

Intellia Therapeutics (NASDAQ:NTLA) reported operational and financial results for Q4 2020, ending with a cash position of $597.4 million. The company successfully dosed its first patient with NTLA-2001, a CRISPR-based therapy for transthyretin amyloidosis (ATTR). It expects to report initial clinical data on NTLA-2001 this year and plans to submit IND applications for NTLA-5001 (AML) and NTLA-2002 (HAE) in mid-2021. R&D expenses increased to $38.2 million, while net loss was $42.2 million for Q4 2020, compared to $28.3 million in Q4 2019.